Minyoung Lee

List of Publications by Year
in descending order

35 papers	**822** citations	687335 **13** h-index	526264 **27** g-index
37 all docs	**37** docs citations	**37** times ranked	**1154** citing authors

#	Article	IF	Citations
1	Renal Tubular Damage Marker, Urinary N-acetyl-β-D-Glucosaminidase, as a Predictive Marker of Hepatic Fibrosis in Type 2 Diabetes Mellitus. Diabetes and Metabolism Journal, 2022, 46, 104-116.	4.7	5
2	A GLP‐1/GLP‐2 receptor dual agonist to treat NASH: Targeting the gut‐liver axis and microbiome. Hepatology, 2022, 75, 1523-1538.	7.3	29
3	Ezetimibe combination therapy with statin for non-alcoholic fatty liver disease: an open-label randomized controlled trial (ESSENTIAL study). BMC Medicine, 2022, 20, 93.	5.5	30
4	Effectiveness and safety of teneligliptin added to patients with type 2 diabetes inadequately controlled by oral triple combination therapy: A multicentre, randomized, double‐blind, and placebo‐controlled study. Diabetes, Obesity and Metabolism, 2022, 24, 1105-1113.	4.4	4
5	Targeting PLD2 in adipocytes augments adaptive thermogenesis by improving mitochondrial quality and quantity in mice. Journal of Experimental Medicine, 2022, 219, .	8.5	5
6	Association between pancreatic fibrosis and development of pancreoprivic diabetes after pancreaticoduodenectomy. Annals of Hepato-biliary-pancreatic Surgery, 2022, 26, S50-S50.	0.1	0
7	Sodium Glucose Cotransporter-2 Inhibitors as an Add-on Therapy to Metformin Plus Dipeptidyl Peptidase-4 Inhibitor in Patients with Type 2 Diabetes. Yonsei Medical Journal, 2022, 63, 539.	2.2	0
8	The Association of Calcium and Vitamin D Use With Implant Survival of Total Knee Arthroplasty: A Nationwide Population-Based Cohort Study. Journal of Arthroplasty, 2021, 36, 542-549.e3.	3.1	7
9	Glycaemic control with add‐on thiazolidinedione or a sodium‐glucose co‐transporter‐2 inhibitor in patients with type 2 diabetes after the failure of an oral triple antidiabetic regimen: A 24‐week, randomized controlled trial. Diabetes, Obesity and Metabolism, 2021, 23, 609-618.	4.4	5
10	Ipragliflozin, an SGLT2 Inhibitor, Ameliorates High-Fat Diet-Induced Metabolic Changes by Upregulating Energy Expenditure through Activation of the AMPK/ SIRT1 Pathway. Diabetes and Metabolism Journal, 2021, 45, 921-932.	4.7	21
11	Lobeglitazone: A Novel Thiazolidinedione for the Management of Type 2 Diabetes Mellitus. Diabetes and Metabolism Journal, 2021, 45, 326-336.	4.7	21
12	Non-Laboratory-Based Simple Screening Model for Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Developed Using Multi-Center Cohorts. Endocrinology and Metabolism, 2021, 36, 823-834.	3.0	1
13	Nonalcoholic fatty liver disease, diastolic dysfunction, and impaired myocardial glucose uptake in patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 2021, 23, 1041-1051.	4.4	11
14	Proteinuria as a significant predictive factor for the progression of carotid artery atherosclerosis in non-albuminuric type 2 diabetes. Diabetes Research and Clinical Practice, 2021, 181, 109082.	2.8	2
15	Magnetic Resonance Imaging-Visible Perivascular Spaces in the Basal Ganglia Are Associated With the Diabetic Retinopathy Stage and Cognitive Decline in Patients With Type 2 Diabetes. Frontiers in Aging Neuroscience, 2021, 13, 666495.	3.4	11
16	Association between pancreatic fibrosis and development of pancreoprivic diabetes after pancreaticoduodenectomy. Scientific Reports, 2021, 11, 23538.	3.3	0
17	Uric Acid Variability as a Predictive Marker of Newly Developed Cardiovascular Events in Type 2 Diabetes. Frontiers in Cardiovascular Medicine, 2021, 8, 775753.	2.4	9
18	Dipeptidyl peptidase-4 inhibitor protects against non-alcoholic steatohepatitis in mice by targeting TRAIL receptor-mediated lipoapoptosis via modulating hepatic dipeptidyl peptidase-4 expression. Scientific Reports, 2020, 10, 19429.	3.3	9

#	Article	IF	Citations
19	<p>Effect of Switching from Linagliptin to Teneligliptin Dipeptidyl Peptidase-4 Inhibitors in Older Patients with Type 2 Diabetes Mellitus</p>. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2020, Volume 13, 4113-4121.	2.4	5
20	Significance of Soluble CD93 in Type 2 Diabetes as a Biomarker for Diabetic Nephropathy: Integrated Results from Human and Rodent Studies. Journal of Clinical Medicine, 2020, 9, 1394.	2.4	10
21	SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease. Nature Communications, 2020, 11, 2127.	12.8	263
22	The Effectiveness of Intermittent Fasting to Reduce Body Mass Index and Glucose Metabolism: A Systematic Review and Meta-Analysis. Journal of Clinical Medicine, 2019, 8, 1645.	2.4	112
23	Nationwide Trends in Pancreatitis and Pancreatic Cancer Risk Among Patients With Newly Diagnosed Type 2 Diabetes Receiving Dipeptidyl Peptidase 4 Inhibitors. Diabetes Care, 2019, 42, 2057-2064.	8.6	32
24	Therapeutic application of the CRISPR system: current issues and new prospects. Human Genetics, 2019, 138, 563-590.	3.8	16
25	Predictors of the Therapeutic Efficacy and Consideration of the Best Combination Therapy of Sodium-Glucose Co-transporter 2 Inhibitors. Diabetes and Metabolism Journal, 2019, 43, 158.	4.7	17
26	Low-dose pioglitazone can ameliorate learning and memory impairment in a mouse model of dementia by increasing LRP1 expression in the hippocampus. Scientific Reports, 2019, 9, 4414.	3.3	55
27	Cover Image, Volume 21, Issue 4. Diabetes, Obesity and Metabolism, 2019, 21, i.	4.4	0
28	Efficacy and Safety of Gemigliptin in Post-Transplant Patients With Type 2 Diabetes Mellitus. Transplantation Proceedings, 2019, 51, 3444-3448.	0.6	3
29	Sodium–glucose cotransporter 2 inhibitors regulate ketone body metabolism via inter–organ crosstalk. Diabetes, Obesity and Metabolism, 2019, 21, 801-811.	4.4	40
30	Higher glucagon-to-insulin ratio is associated with elevated glycated hemoglobin levels in type 2 diabetes patients. Korean Journal of Internal Medicine, 2019, 34, 1068-1077.	1.7	17
31	Glycated Albumin Is a More Useful Glycation Index than HbA1c for Reflecting Renal Tubulopathy in Subjects with Early Diabetic Kidney Disease. Diabetes and Metabolism Journal, 2018, 42, 215.	4.7	10
32	Elevated urinary N-acetyl-β-D-glucosaminidase is associated with high glycoalbumin-to-hemoglobin A1c ratio in type 1 diabetes patients with early diabetic kidney disease. Scientific Reports, 2018, 8, 6710.	3.3	13
33	Elevated N -acetyl-β- d -glucosaminidase, a urinary tubular damage marker, is a significant predictor of carotid artery atherosclerosis in type 1 diabetes, independent of albuminuria: A cross-sectional study. Journal of Diabetes and Its Complications, 2018, 32, 777-783.	2.3	6
34	Current Helicobacter pylori infection is significantly associated with subclinical coronary atherosclerosis in healthy subjects: A cross-sectional study. PLoS ONE, 2018, 13, e0193646.	2.5	53
35	Glycated Albumin Is a More Useful Glycation Index than HbA1c for Reflecting Renal Tubulopathy in Subjects with Early Diabetic Kidney Disease. Diabetes and Metabolism Journal, 2018, , .	4.7	0